VERILOID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VERILOID (VERILOID).
VERILOID is a synthetic alkaloid that acts as a ganglionic blocker, inhibiting nicotinic acetylcholine receptors at autonomic ganglia, leading to reduced sympathetic and parasympathetic outflow. This results in vasodilation and decreased peripheral vascular resistance, lowering blood pressure.
| Metabolism | Primarily hepatic metabolism via unknown pathways; excretion is renal. |
| Excretion | Renal excretion accounts for approximately 60% as unchanged drug; hepatic metabolism contributes 30% with biliary-fecal elimination of metabolites, totaling ~10% fecal. |
| Half-life | Terminal elimination half-life is 3-5 hours, clinically relevant for dose scheduling to maintain steady-state levels. |
| Protein binding | 40-50% bound to albumin. |
| Volume of Distribution | 0.5-0.8 L/kg, indicating moderate tissue distribution. |
| Bioavailability | Oral: 20-30% due to first-pass metabolism; intravenous: 100%. |
| Onset of Action | Intravenous: 1-2 minutes; oral: 15-30 minutes. |
| Duration of Action | Intravenous: 0.5-1 hour; oral: 2-4 hours, with rapid offset due to redistribution. |
| Molecular Weight | 869.1 |
Intravenous: 0.1-0.5 mg/kg bolus, followed by 0.5-2 mcg/kg/min continuous infusion. Oral: 20-80 mg every 6-8 hours.
| Dosage form | TABLET |
| Renal impairment | GFR 30-59 mL/min: reduce dose by 25%. GFR 15-29 mL/min: reduce dose by 50%. GFR <15 mL/min: use with caution, maximum dose 20 mg per day. |
| Liver impairment | Child-Pugh Class A: no adjustment. Class B: reduce dose by 50%. Class C: contraindicated. |
| Pediatric use | Weight-based: 0.05-0.2 mg/kg/dose IV every 6-8 hours, max 10 mg/dose. Continuous infusion: 0.1-0.5 mcg/kg/min. Oral: 0.5-2 mg/kg/day divided every 6-8 hours, max 80 mg/day. |
| Geriatric use | Initiate at 50% of usual adult dose; maximum oral dose 40 mg per day. Monitor for hypotension and bradycardia. |
| 1st trimester | Contraindicated due to risk of fetal harm; no adequate studies in pregnant women. |
| 2nd trimester | Contraindicated; may cause fetal bradycardia and reduced placental perfusion. |
| 3rd trimester | Contraindicated; may cause neonatal hypotension, bradycardia, and hypoglycemia. |
Clinical note
Comprehensive clinical and safety monograph for VERILOID (VERILOID).
| Placental transfer | Crosses placenta; documented in animal and human studies. |
| Breastfeeding | Excreted into breast milk in small amounts; use with caution due to potential for infant bradycardia and hypotension. |
| Lactation Rating |
■ FDA Black Box Warning
None currently; however, due to risk of severe hypotension and adverse effects, its use is limited and not recommended for routine management.
| Serious Effects |
PregnancyBreastfeeding (relative)Severe hypotensionCardiogenic shockAV block (2nd or 3rd degree)
| Precautions | May cause severe orthostatic hypotension, syncope, and dizziness., Risk of impaired circulation in patients with coronary or cerebral atherosclerosis., Caution in patients with renal impairment due to accumulation risk., May worsen symptoms in patients with peptic ulcer disease due to increased gastric secretion., Abrupt withdrawal may lead to rebound hypertension. |
| Food/Dietary | Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products) as they may cause hypertensive crisis. Limit caffeine intake due to potential additive cardiovascular effects. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | No human data; animal studies not available. Risk cannot be excluded. Avoid use in first trimester unless essential. Not recommended in pregnancy. |
| Fetal Monitoring | Monitor maternal blood pressure and heart rate; assess fetal heart rate and growth if used in pregnancy. |
| Fertility Effects | No human data; animal studies not available. Potential to impair fertility if hypotensive episodes occur. |
| Clinical Pearls | Veriloid (veratrum viride alkaloids) is a potent hypotensive agent that can cause severe bradycardia and hypotension. Monitor heart rate and blood pressure closely during administration. It is rarely used due to narrow therapeutic index and risk of toxicity. Administer only under continuous medical supervision. |
| Patient Advice | Take this medication exactly as prescribed; do not change dose or stop without consulting your doctor. · You may experience dizziness, lightheadedness, or fainting; avoid driving or operating machinery until you know how the drug affects you. · Report any slow heart rate, chest discomfort, or severe nausea/vomiting immediately. · Avoid alcohol and other medications that lower blood pressure without medical advice. · Do not take with cold or allergy medications containing decongestants. |